Potassium citrate

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Potassium citrate
Accession Number
DB09125
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.

Structure
Thumb
Synonyms
  • tripotassium citrate
Active Moieties
NameKindUNIICASInChI Key
Potassium cationionic295O53K15224203-36-9NPYPAHLBTDXSSS-UHFFFAOYSA-N
Citric acidunknownXF417D3PSL77-92-9KRKNYBCHXYNGOX-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium CitrateTablet10 meq/1OralUpsher-Smith Laboratories, LLC2006-09-01Not applicableUs00245 0071 11 nlmimage10 f00df86f
Potassium CitrateTablet5 meq/1OralUpsher-Smith Laboratories, LLC2006-09-01Not applicableUs00245 0070 11 nlmimage10 234691d4
Urocit KTablet, extended releaseOralMission Pharmacal Company1995-01-01Not applicableCanada
Urocit-KTablet, extended release10 meq/1OralREMEDYREPACK INC.2016-12-27Not applicableUs
Urocit-KTablet, extended release15 meq/1OralMission Pharmacal Company2010-01-27Not applicableUs0178 061520180907 15195 1ux5bno
Urocit-KTablet, extended release15 meq/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUs00178 0615 01 nlmimage10 581dac0d
Urocit-KTablet, extended release10 meq/1OralMission Pharmacal Company1992-09-01Not applicableUs
Urocit-KTablet, extended release10 meq/1OralPhysicians Total Care, Inc.2003-04-17Not applicableUs
Urocit-KTablet, extended release1080 mgOralMission Pharmacal Company2011-02-11Not applicableCanada
Urocit-KTablet, extended release5 meq/1OralMission Pharmacal Company1985-09-01Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium CitrateTablet, extended release5 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release540 mg/1OralRising Pharmaceuticals2006-06-192011-02-03Us
Potassium CitrateTablet, extended release5 meq/1OralActavis Pharma, Inc.2018-05-30Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release1080 mg/1OralMed-Health Pharma, LLC.2011-04-102012-04-25Us
Potassium CitrateTablet, extended release10 meq/1Oralbryant ranch prepack2018-05-30Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release540 mg/1OralMed-Health Pharma, LLC.2011-04-102012-04-25Us
Potassium CitrateTablet15 meq/1OralBiocomp Pharma, Inc.2013-12-23Not applicableUs44523 0415 01 nlmimage10 4a3ea535
Potassium CitrateTablet, extended release15 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
B6 Plus TabPotassium citrate (50 mg) + Magnesium oxide (50 mg) + Niacin (20 mg) + Pyridoxine hydrochloride (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralVita Health Products Inc1979-12-312002-08-01Canada
Formula No. 2 Plus K LiqPotassium citrate (19.5 mg) + Ascorbic acid (2 mg)LiquidOralGolden Pride/Rawleigh1993-12-311996-09-30Canada
LytrenPotassium citrate (270 mg) + Citric acid (26 mg) + Dextrose, unspecified form (2 g) + Sodium chloride (263 mg) + Sodium citrate (49 mg)LiquidOralMead Johnson Nutritionals1985-12-312003-07-08Canada
Lytren Rhs LiqPotassium citrate (217 mg) + Citric acid (26.1 mg) + Sodium chloride (375 mg) + Sodium citrate (107 mg)LiquidOralMead Johnson Nutritionals1990-12-312000-09-11Canada
RehydralytePotassium citrate (2.04 mg) + Dextrose, unspecified form (25 mg) + Sodium chloride (3.8 mg) + Sodium citrate (.78 mg)LiquidOralRoss Laboratories, Division Of Abbott Laboratories Ltd.1988-12-312008-04-16Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cytra 3Potassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL)SyrupOralPegasus Laboratories2006-05-052009-10-17Us
Cytra 3Potassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL)SyrupOralCypress Pharmaceuticals, Inc2008-07-292014-10-11Us
Cytra-KPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralCypress Pharmaceuticals, Inc.2008-09-302014-10-11Us
Cytra-K CrystalsPotassium citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralCypress Pharmaceuticals, Inc.2003-05-01Not applicableUs
Potassium Citrate and Citric AcidPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralPharmaceutical Associates, Inc.1997-10-07Not applicableUs
Potassium Citrate Citric Acid CrystalsPotassium citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralVirtus Pharmaceuticals LLC2014-06-132019-04-30Us
Potassium Citrate-Citric AcidPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2014-10-202015-12-31Us
Potassium Citrate-Citric AcidPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-03Us
Potassium Citrate-Sodium Citrate-Citric AcidPotassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate dihydrate (500 mg/5mL)SolutionOralMethod Pharmaceuticals2014-10-202015-12-31Us
Potassium Citrate-Sodium Citrate-Citric AcidPotassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate dihydrate (500 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-03Us
Categories
UNII
86R1NVR0HW
CAS number
Not Available
Weight
Average: 306.394
Monoisotopic: 305.89464697
Chemical Formula
C6H5K3O7
InChI Key
QEEAPRPFLLJWCF-UHFFFAOYSA-K
InChI
InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
IUPAC Name
tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
SMILES
[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

Pharmacology

Indication

For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.

Associated Conditions
Pharmacodynamics

Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.

Mechanism of action

After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.

Route of elimination

Urinary; less than 5% unchanged.

Half life
Not Available
Clearance
Not Available
Toxicity

LD50 (dog): Intravenous 176 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(1,2,6,7-3H)Testosterone(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Potassium Citrate.
(R)-warfarinThe risk or severity of bleeding can be increased when Potassium Citrate is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Potassium Citrate is combined with (S)-Warfarin.
1-Testosterone1-Testosterone may increase the anticoagulant activities of Potassium Citrate.
18-methyl-19-nortestosterone18-methyl-19-nortestosterone may increase the anticoagulant activities of Potassium Citrate.
2,5-Dimethoxy-4-ethylamphetamineThe excretion of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when combined with Potassium Citrate.
2,5-Dimethoxy-4-ethylthioamphetamineThe excretion of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when combined with Potassium Citrate.
3,5-Diiodotyrosine3,5-Diiodotyrosine may increase the anticoagulant activities of Potassium Citrate.
4-Bromo-2,5-dimethoxyamphetamineThe excretion of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when combined with Potassium Citrate.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Potassium Citrate is combined with 4-hydroxycoumarin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Monograph [Link]
  2. safety data sheet [Link]
External Links
PubChem Compound
13344
PubChem Substance
310265041
ChemSpider
12775
ChEBI
64733
ChEMBL
CHEMBL1200458
Wikipedia
Potassium_citrate
ATC Codes
A12BA02 — Potassium citrate
AHFS Codes
  • 40:12.00 — Replacement Preparations
FDA label
Download (81.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBone Diseases / Metabolic Acidosis / Mineral Metabolism / Physical Capacity / Renal Transplant Patients1
2RecruitingTreatmentHigh Blood Pressure (Hypertension)1
2, 3RecruitingTreatmentCystine renal calculi1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHypercalciuria / Kidney Stones1
3Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension)1
3RecruitingPreventionDistal Renal Tubular Acidosis1
3Unknown StatusPreventionNephrocalcinosis1
4CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentKidney Stones / Urolithiasis1
4Enrolling by InvitationTreatmentKidney Stones1
4RecruitingPreventionUrolithiasis1
4RecruitingTreatmentDuodenal Ulcer Due to Helicobacter Pylori1
4Unknown StatusTreatmentBone Diseases, Metabolic / Postmenopausal Osteoporosis (PMO)1
Not AvailableCompletedDiagnosticKidney Stones1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
SyrupOral
SolutionOral
Granule, for solutionOral
TabletOral10 meq/1
TabletOral5 meq/1
Tablet, extended releaseOral1080 mg/1
Tablet, extended releaseOral5 meq/1
Tablet, extended releaseOral540 mg/1
TabletOral15 meq/1
LiquidOral
Tablet, extended releaseOral
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral1080 mg
Tablet, extended releaseOral15 meq/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility39.4 mg/mLALOGPS
logP-0.7ALOGPS
logP-1.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)3.05ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area140.62 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity68.14 m3·mol-1ChemAxon
Polarizability14.23 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Tricarboxylic acids and derivatives
Direct Parent
Tricarboxylic acids and derivatives
Alternative Parents
Tertiary alcohols / Carboxylic acid salts / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Tricarboxylic acid or derivatives / Tertiary alcohol / Carboxylic acid salt / Organic alkali metal salt / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic potassium salt / Organic salt
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
potassium salt (CHEBI:64733)

Drug created on September 23, 2015 10:41 / Updated on November 20, 2019 12:30